Martin David Harp

Christina Y Weng, MD, MBA sat down to discuss the Retina Ophthalmic Technology Assessment Symposium and her journal on teleretinal screening for diabetic eye disease at this year's American Academy of Ophthalmology meeting held in Chicago, Illinois.

Abdelrahman Elhusseiny, MD, MSc, sat down with David Hutton of Ophthalmology Times to discuss his presentation on the risk of posterior capsular rupture in fellow eyes of cataract surgery at this year's American Academy of Ophthalmology meeting being held in Chicago, Illinois.

David Eichenbaum, MD and Riad Sherif, MD, CEO of Oculis will present the updates with additional info on topline results from the ACUITY Phase 2 trial of OCS-05 for the treatment of acute optic neuritis (AON).

MELT-300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery.

The Eye Care Network adds a longstanding, CME-certified to its live event programming.

Ten of the institute's ophthalmologists will present their work in more than 20 sessions with a wide range of topics

The trial is assessing the safety and efficacy of EO2002 for the treatment of corneal edema.

The resubmission comes after receiving a Complete Response Letter at the end of 2023.

Ciclosporin 0.1% eye drops solution will be marketed under the brand name Vevizye in the EU for the treatment of dry eye disease.

The company’s flagship product is Reti-CVD, an AI diagnostic solution that autonomously assesses future cardiovascular disease risk using a retina scan.

The TECNIS Odyssey IOL is a new full vision range IOL built on the TECNIS platform.

Clobetasol is FDA-approved for the treatment of post-operative inflammation and pain following ocular surgery.

Additionally, FDA grants Fast Track Designation to brepocitinib for non-infectious uveitis.

The agency confirmed its June 2024 negative opinion after Apellis requested re-examination of EMA's initial opinion.

Vyznova is for the treatment of bullous keratopathy of the cornea, a sight-threatening and debilitating condition affecting the endothelial cells of the cornea.

The data were presented at the Keystone Symposium Targeting Dry Age-related Macular Degeneration: Pathophysiology and Emerging Therapies.

Robert Osher, MD, sat down with David Hutton of Ophthalmology Times to discuss the Lifetime Achievement award he received from the European Society of Cataract and Refractive Surgeons.

Efferocytosis’ role in retinopathy is largely unknown despite knowledge of the process in other diseases.

Ripple will lead preclinical development of RTC-620 while AbbVie will lead the clinical and commercialization activities upon exercise of option-to-license agreement.

IVW-1001 is a novel TRPM8 agonist delivered via ophthalmic eyelid wipe, being developed to treat DED.

Meeting in Stockholm provides education, updates, and a taste of culture.

According to the company, the pilot study showed procedural feasibility of ophthalmic artery angioplasty in the treatment of vascular lesions associated with geographic atrophy (GA).

Visual acuity and macular anatomy were maintained, with some changes in fluid management.

Results showed that patients who received veligrotug, an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, had “statistically significant and clinically meaningful improvements across [multiple] key disease endpoints at the primary efficacy analysis timepoint of 15 weeks.”

Jennifer Lim, MD, FARVO, FASRS, discusses her presentation on differential artery-vein analysis and how it improves OCTA performance for AI classification of diabetic retinopathy at the annual Retina Society meeting being held this year in Lisbon, Portugal.

Theodore Leng, MD, MS, sat down with David Hutton of Ophthalmology Times to discuss his presentation on Progression of Newly Diagnosed Geographic Atrophy: An Observational, Retrospective US-based Cohort Study at the annual Retina Society meeting being held this year in Lisbon, Portugal

The Retina Society meeting will take place in Lisbon, Portugal from September 11-15, 2024.

The contract research organization and technology solution is for the execution of ophthalmology clinical trials.

MK-3000, formally known as EYE103, is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wnt signaling pathway.

The trial is evaluating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia.